Phase I Clinical Trial of Camptothecin-20-O-Propionate Hydrate (CZ48)

Trial Profile

Phase I Clinical Trial of Camptothecin-20-O-Propionate Hydrate (CZ48)

Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Camptothecin (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Cao Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2018.
    • 02 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 May 2018.
    • 02 Oct 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top